Please login to the form below

Not currently logged in
Email:
Password:

oseltamivir

This page shows the latest oseltamivir news and features for those working in and with pharma, biotech and healthcare.

Roche’s Xofluza pill wins FDA approval for post-exposure flu prevention

Roche’s Xofluza pill wins FDA approval for post-exposure flu prevention

It has already been shown to be effective against a wide range of flu viruses, including those resistant to Roche’s now off-patent and former blockbuster flu treatment, Tamiflu (oseltamivir).

Latest news

  • Roche scores another FDA approval for Xofluza Roche scores another FDA approval for Xofluza

    oseltamivr. The approval was based on results from Roche’s phase 3 CAPSTONE-2 trial of Xofluza, compared to oseltamivir or placebo, in people aged 12 or over, who met the ... However, similar efficacy results were seen between Xofluza and oseltamivir

  • UK bans some drug exports to preserve NHS stocks UK bans some drug exports to preserve NHS stocks

    It applies mainly to hormone replacement therapies but also includes all adrenaline pens, hepatitis B vaccines and the influenza drug oseltamivir, sold by Roche as Tamiflu, amongst other drugs.

  • Roche’s flu drug Xofluza scores phase 3 primary endpoint Roche’s flu drug Xofluza scores phase 3 primary endpoint

    It has already been shown to be effective against a wide range of flu viruses, including those resistant to Roche’s now off-patent and former blockbuster flu treatment, Tamiflu (oseltamivir). ... Roche is keen to produce more evidence of the

  • Roche’s new flu pill Xofluza approved in US Roche’s new flu pill Xofluza approved in US

    Xofluza significantly reduced the duration of flu symptoms compared to placebo, and demonstrated similar efficacy compared to oseltamivir. ... Analysts say the new treatment will have to generate more evidence of significant benefits in these high risk

  • Encouraging data for Roche flu drug ahead of FDA decision Encouraging data for Roche flu drug ahead of FDA decision

    Analysts say the new treatment will have to generate more evidence of significant benefits in these high risk groups in order for healthcare systems to switch away from generic oseltamivir.

More from news
Approximately 0 fully matching, plus 35 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Windrose Consulting Group

Founded in 2015, Windrose Consulting Group is a privately-held global strategy firm that partners with life science companies to maximize...

Latest intelligence

How innovating study sites can improve patient recruitment efficiency
There are so many ways that clinical trials have innovated over the last few years. There is now a larger focus on making trials more patient-centric, more virtualised, and more...
PME-MAY21-Cover
Avoiding A Series of Unfortunate Events: launch lessons from lockdown
Chris Ross takes a novel look at launch excellence through the lens of COVID-19 and explores how pharma’s launch leaders are rewriting the story...
6 reasons patients drop out of clinical trials and 6 ways to fix it
If you’ve successfully recruited patients for your clinical trial, but one by one, they begin to drop out, then this information could be for you....